Retatrutide After Phase 3: What Four Trial Readouts Actually Showed

Standing note: Retatrutide (LY3437943) is an investigational compound. It holds no marketing authorisation from the MHRA, FDA, EMA or any other regulator anywhere in the world. Nothing in this article is medical advice, and nothing in it should be read as a suggestion that the compound can be legitimately obtained outside a registered clinical trial. It cannot.

For three years Retatrutide sat in an awkward position: a Phase 2 result so far outside the historical range that it dominated coverage, attached to an evidence base too thin to support any of the claims being made about it. That gap has now closed. Between December 2025 and July 2026, four Phase 3 trials reported topline results. The compound is no longer a promising signal — it is a late-stage asset with data across obesity, type 2 diabetes, cardiovascular disease and osteoarthritis populations.

This article covers what those readouts showed, what the triple-receptor design is actually doing mechanistically, and — the part most coverage skips — why the supply situation around this particular compound is unlike anything else in the peptide space.

Where the evidence stands, in short

Retatrutide is a once-weekly triple agonist of the GLP-1, GIP and glucagon receptors, developed by Eli Lilly. It is the first compound to engage all three.

The pivotal obesity trial, TRIUMPH-1, enrolled 2,339 adults and reported mean weight loss of 28.3% at 80 weeks on the top dose against 2.2% on placebo. A prespecified extension in participants with a baseline BMI of 35 or above reached 30.3% at 104 weeks, with no plateau evident.

Nearly half of participants on the top dose — 45.3% — lost 30% or more of body weight, a threshold historically associated with bariatric surgery rather than pharmacotherapy.

The safety picture is dominated by gastrointestinal effects during titration, consistent with the incretin class, alongside a dysesthesia signal that emerged in Phase 3 and was not prominent in Phase 2.

Regulatory filing is expected in early 2027. Approval, if it comes, would follow later. There is no legitimate route to this compound before then.

What Retatrutide is

Retatrutide is a synthetic peptide built on a modified glucagon backbone, with amino acid substitutions that broaden receptor binding across three class B G-protein-coupled receptors, and a fatty-acid moiety that extends half-life enough to support once-weekly subcutaneous dosing.

The three targets:

• GLP-1R — the glucagon-like peptide-1 receptor
• GIPR — the glucose-dependent insulinotropic polypeptide receptor
• GCGR — the glucagon receptor

It comes from the same developer as tirzepatide, which is worth noting because it means the comparison against tirzepatide is not a competitive framing — it is a company iterating on its own mechanism.

One technical detail with regulatory consequences: Lilly is expected to file a Biologics License Application rather than a New Drug Application, because retatrutide is classified as a biologic. This matters more than it sounds. It removes the compounding pathway entirely. The shortage-driven route that briefly allowed compounded semaglutide and tirzepatide has no equivalent here.

Why three receptors instead of two

The obvious reading of a triple agonist is "more of the same, turned up." That is not the design logic. Each receptor moves a different variable in the energy-balance equation.

Receptor	Mechanism	What it contributes
GLP-1R	Slows gastric emptying, blunts postprandial glucose, acts on hypothalamic appetite circuits	Reduced intake
GIPR	Improves insulin sensitivity, modulates adipose nutrient partitioning, appears to blunt GLP-1-driven nausea	Tolerability and fat handling
GCGR	Raises resting energy expenditure, drives hepatic fat oxidation and lipolysis	Increased output

GLP-1 and GIP both work primarily by reducing what goes in. Glucagon works by increasing what goes out. That is the structural difference, and it is why the compound is not simply a stronger tirzepatide.

There is a reason nobody did this sooner. Unopposed glucagon agonism raises hepatic glucose output and worsens glycaemic control — it is the wrong direction for a metabolic drug. Retatrutide's design assumes the GLP-1 arm's insulinotropic effect counterbalances that. This is a genuine pharmacological bet, and until Phase 3 there was reasonable doubt about whether the balance would hold across populations.

The Phase 3 diabetes data suggests it does. In TRIUMPH-2, which enrolled 1,152 participants with obesity and type 2 diabetes, the compound produced up to 20.8% weight loss alongside HbA1c reductions of up to 1.6 percentage points at 80 weeks. The glucagon arm did not sabotage glycaemic control in the population where it would most obviously have done so. For a fuller treatment of what these drugs leave behind, see our piece on GLP-1 agonists and metabolic flexibility.

The Phase 3 record

Four trials, four positive readouts.

Trial	Population	n	Headline result
TRIUMPH-4 (Dec 2025)	Obesity/overweight + knee osteoarthritis	445	28.7% weight loss at 68 weeks (12 mg), plus reduction in knee pain
TRIUMPH-1 (May 2026)	Obesity/overweight + ≥1 comorbidity, no diabetes	2,339	28.3% at 80 weeks (12 mg); 30.3% at 104 weeks in BMI ≥35 extension
TRIUMPH-2 (Jul 2026)	Obesity + type 2 diabetes	1,152	Up to 20.8% weight loss, up to −1.6pp HbA1c at 80 weeks
TRIUMPH-3 (Jul 2026)	Obesity + established cardiovascular disease	1,949	Up to 22.6% at 80 weeks, with improvements in triglycerides, blood pressure and inflammatory markers

TRIUMPH-1 is the trial that anchors the regulatory filing, so it deserves the closer look.

Arm	Mean weight change, 80 weeks
Placebo	−2.2%
Retatrutide 4 mg	−19.0%
Retatrutide 9 mg	−25.9%
Retatrutide 12 mg	−28.3%

Beyond the means, three findings shape how the result should be read.

The dose–response is unusually flat at the bottom. The 4 mg arm — reached with a single escalation step — produced 19.0%, which is in the same territory as top-dose tirzepatide. That matters clinically, because it suggests meaningful benefit is available without pushing to the doses where tolerability degrades. Discontinuation due to adverse events on 4 mg was reported as lower than placebo.

Categorical outcomes were strong. 65.3% of participants on 12 mg finished below a BMI of 30 — out of the obesity category entirely. Among those who entered with a BMI of 40 or above, 37.5% got there.

The curve had not flattened. The 104-week extension continued to show loss. Weight-loss curves in this class typically plateau somewhere between 60 and 72 weeks. This one did not, across two full years.

A nested substudy within TRIUMPH-1, presented at the American Diabetes Association meeting in June 2026, examined obstructive sleep apnoea and reported a 60.6% reduction in apnoea-hypopnoea index from a severe baseline of 58.6 events per hour.

Reading the numbers honestly

A 28.3% mean in a Phase 3 trial is not a 28.3% expectation in routine care, and the gap is not small.

Trial participants receive protocolised titration, structured dietary counselling, regular contact and adherence support. None of that transfers automatically to a prescription and a monthly pharmacy collection. Effect sizes in this class have consistently compressed post-marketing.

The 30.3% figure needs a further caveat, and it is the one most often dropped in coverage. It comes from a 532-participant extension restricted to people who had a baseline BMI of 35 or higher, completed the main trial, and tolerated their assigned dose without discontinuation or permanent reduction. It is a selected subgroup by construction — not the average across everyone who started.

Both numbers are real. Neither is the number an individual should expect.

Safety

The adverse event profile is broadly what the incretin class predicts, with one addition worth flagging.

Gastrointestinal effects — nausea, vomiting, diarrhoea, constipation — dominate and cluster during dose escalation. Rates in TRIUMPH-4 ran higher than previously reported for semaglutide or tirzepatide, and discontinuation at 12 mg exceeded 9 mg. TRIUMPH-1 reported a lower overall discontinuation rate at 11.3% against TRIUMPH-4's 18.2%, though the populations differ.

The new signal is dysesthesia — abnormal skin sensation — reported in up to 20.9% of participants on 12 mg in TRIUMPH-4, generally mild and mostly resolving during treatment. Urinary tract infections also appeared. Neither was a prominent feature of the Phase 2 data, which is a reasonable illustration of why larger and longer trials exist.

A modest resting heart rate increase has been observed, consistent with the class. Whether that carries any cardiovascular cost has not been answered by a dedicated outcomes trial.

Against semaglutide and tirzepatide

	Semaglutide	Tirzepatide	Retatrutide
Receptors	GLP-1	GLP-1 + GIP	GLP-1 + GIP + glucagon
Status (Aug 2026)	Approved	Approved	Investigational, Phase 3 complete
Pivotal result	~15% at 68 wks (STEP-1)	~21% at 72 wks (SURMOUNT-1)	28.3% at 80 wks (TRIUMPH-1)
Dominant mechanism	Intake reduction	Intake reduction + insulin sensitisation	Intake reduction + energy expenditure
Long-term outcomes	Extensive	Accumulating	Absent

Two cautions on that table. Trial durations differ — 80 weeks against 68 and 72 — and longer exposure means more of the curve. And no head-to-head Phase 3 comparison has been published, so all cross-trial comparison carries the usual caveats about differing populations, protocols and eras.

The hepatic signal is where the mechanism looks most distinctive. Phase 2 imaging showed liver fat reductions in the region of 86% at the top dose — among the largest reported for any pharmacotherapy. If the glucagon arm is producing direct hepatic effects rather than effects secondary to weight loss, that has implications for metabolic dysfunction-associated steatotic liver disease that go well beyond the weight number. Dedicated MASLD trials are running.

What remains unknown

Question	Status
Weight loss exceeding dual agonists	Established across four Phase 3 trials
Glycaemic safety despite glucagon arm	Supported by TRIUMPH-2 and TRANSCEND-T2D-1
Preferential visceral and hepatic fat loss	Suggested by imaging, not yet confirmed at Phase 3 scale
Cardiovascular outcomes	No completed CVOT. TRIUMPH-3 shows risk-marker improvement, which is not the same thing
Regain after discontinuation	No published data. This is the most consequential gap
Lean mass preservation	Not a mandated endpoint. Depends heavily on what patients do alongside
Multi-year safety	Two years maximum exposure. Not established

The discontinuation question deserves emphasis. Every agent in this class shows substantial regain on cessation. Whether a larger initial loss resets to a lower set point or simply falls further is unanswered, and no trial currently reporting is designed to answer it.

Supply: the part most coverage gets wrong

This is where retatrutide diverges sharply from every other compound discussed in peptide research circles, and where the situation has changed materially in 2026.

There is no legitimate source. Not a restricted one — none. Legitimate access exists solely within Lilly-run trials. Because retatrutide is a biologic with no approved active pharmaceutical ingredient, compounding pharmacies cannot lawfully produce it, and the FDA stated plainly in June 2026 that sales to consumers are illegal and that it cannot lawfully be compounded.

In August 2026, Lilly filed six lawsuits against US entities selling retatrutide, targeting compounding pharmacies, medical spas and online sellers. Several defendants were targeted specifically over "research use only" labelling, on the argument that the framing was a fiction and the product was intended for human use. Lilly stated it had referred more than 200 entities to the FDA, the Department of Justice, state attorneys general and licensing boards, and had identified more than 14,000 websites, advertisements and listings across over 100 countries. It also publicly called on payment processors, e-commerce platforms and logistics companies to withdraw services from these sellers.

The practical reading for anyone following the research: material sold online under a "retatrutide" or "R3TA" label is not the compound studied in TRIUMPH. It has not been characterised against the trial molecule, its identity is unverified, and its manufacture is typically outside any inspected facility. The published efficacy and safety data describes a specific, well-characterised molecule produced under GMP conditions. It says nothing about the contents of an unverified vial.

That is not a compliance caveat appended for form. Every number in this article is a statement about a molecule that is not available for purchase.

The composition question

Any intervention producing rapid, large weight loss raises the same question, and it is the one the trial endpoints answer least well: is the body that remains in better condition than the body that started?

Rapid loss from any cause — surgical, pharmacological or dietary — carries lean mass with it, conventionally cited in the range of 20–35% of total mass lost. The two interventions with consistent evidence for limiting that are adequate protein intake and resistance training.

The TRIUMPH protocols did not mandate either. They specified diet and physical activity as adjuncts without prescribing a training stimulus or a protein target. So the composition outcome in real-world use will be determined largely outside the drug — by whether the person taking it lifts and eats accordingly.

The theoretical argument for retatrutide here is interesting and unproven: if the glucagon arm raises energy expenditure and drives hepatic fat oxidation, a greater share of the loss may come from fat rather than lean tissue than intake-suppression alone would produce. The imaging data is suggestive. It has not been tested with DXA-based lean mass as a primary endpoint over multi-year exposure, and until it is, the mechanism is a hypothesis rather than a finding.

Timeline

Lilly is expected to file a Biologics License Application in early 2027, shifted later than earlier guidance. On standard review timelines, a US decision would fall in late 2027. MHRA authorisation typically follows FDA by six to twelve months, and a NICE technology appraisal would come later still.

No regulator has confirmed any of this. These are projections from standard timelines, not commitments, and Phase 3 data reading out positively is not the same as a compound being approved.

Frequently asked

---

This article summarises publicly reported clinical trial data for educational purposes. It is not medical advice, and it is not a product recommendation. Retatrutide is not approved for human use in any country and cannot lawfully be sold to consumers.